Reviewer's report
Title:Hepatocellular carcinoma associated with Budd-Chiari syndrome: imaging
features and transcatheter arterial chemoembolization
Version: 2Date:28 March 2013
Reviewer: marco montorsi
Reviewer's report:
Major comments
The authors describe their experience regarding the diagnosis and therapy of
patients with Budd-Chiari syndrome (BCS) with hepatocellular carcinoma (HCC).
The population includes 14 patients with HCC. The purpose of the paper is
mainly to show imaging features of such patients, as stated in the abstract.
However, the authors focus the attention not only on imaging features of
diagnosis and therapy, but also on the effectiveness of the different treatments
(TACE, RFA, resection, transplantation, etc...). They conclude that TACE can
effectively control tumor progression.
The short data on survival of patients treated with TACE are insufficient to prove
that TACE is superior to any other tested treatment. Moreover, 14 patients are a
small sample, inadequate to verify significant differences from a statistical
standpoint.
I would suggest to remove the survival data, focusing the paper on the
interventional radiology treatments of BCS and BCS with HCC. It would be of
some interest to have also a short literature review of such arguments.
Minor comments
There are somel typing erros, which must be fixed.
Level of interest: An article whose findings are important to those with closely
related research interests
Quality of written English: Needs some language corrections before being
published
Statistical review: No, the manuscript does not need to be seen by a
statistician.
Declaration of competing interests:
I declare that I have no competing interests.
Reviewer's report
Title:Hepatocellular carcinoma associated with Budd-Chiari syndrome: imaging
features and transcatheter arterial chemoembolization
Version: 2Date:28 March 2013
Reviewer: marco montorsi
Reviewer's report:
Major comments
The authors describe their experience regarding the diagnosis and therapy of
patients with Budd-Chiari syndrome (BCS) with hepatocellular carcinoma (HCC).
The population includes 14 patients with HCC. The purpose of the paper is
mainly to show imaging features of such patients, as stated in the abstract.
However, the authors focus the attention not only on imaging features of
diagnosis and therapy, but also on the effectiveness of the different treatments
(TACE, RFA, resection, transplantation, etc...). They conclude that TACE can
effectively control tumor progression.
The short data on survival of patients treated with TACE are insufficient to prove
that TACE is superior to any other tested treatment. Moreover, 14 patients are a
small sample, inadequate to verify significant differences from a statistical
standpoint.
I would suggest to remove the survival data, focusing the paper on the
interventional radiology treatments of BCS and BCS with HCC. It would be of
some interest to have also a short literature review of such arguments.
Minor comments
There are somel typing erros, which must be fixed.
Level of interest: An article whose findings are important to those with closely
related research interests
Quality of written English: Needs some language corrections before being
published
Statistical review: No, the manuscript does not need to be seen by a
statistician.
Declaration of competing interests:
I declare that I have no competing interests.
Please review this paper.
user
Reviewer's report
Title:Hepatocellular carcinoma associated with Budd-Chiari syndrome: imaging
features and transcatheter arterial chemoembolization
Version: 2Date:28 March 2013
Reviewer: marco montorsi
Reviewer's report:
Major comments
The authors describe their experience regarding the diagnosis and therapy of
patients with Budd-Chiari syndrome (BCS) with hepatocellular carcinoma (HCC).
The population includes 14 patients with HCC. The purpose of the paper is
mainly to show imaging features of such patients, as stated in the abstract.
However, the authors focus the attention not only on imaging features of
diagnosis and therapy, but also on the effectiveness of the different treatments
(TACE, RFA, resection, transplantation, etc...). They conclude that TACE can
effectively control tumor progression.
The short data on survival of patients treated with TACE are insufficient to prove
that TACE is superior to any other tested treatment. Moreover, 14 patients are a
small sample, inadequate to verify significant differences from a statistical
standpoint.
I would suggest to remove the survival data, focusing the paper on the
interventional radiology treatments of BCS and BCS with HCC. It would be of
some interest to have also a short literature review of such arguments.
Minor comments
There are somel typing erros, which must be fixed.
Level of interest: An article whose findings are important to those with closely
related research interests
Quality of written English: Needs some language corrections before being
published
Statistical review: No, the manuscript does not need to be seen by a
statistician.
Declaration of competing interests:
I declare that I have no competing interests.
assistant